vs
Apellis Pharmaceuticals, Inc.（APLS）与BED BATH & BEYOND, INC.（BBBY）财务数据对比。点击上方公司名可切换其他公司
BED BATH & BEYOND, INC.的季度营收约是Apellis Pharmaceuticals, Inc.的1.2倍（$247.8M vs $199.9M），BED BATH & BEYOND, INC.净利率更高（-6.6% vs -29.5%，领先22.9%），BED BATH & BEYOND, INC.同比增速更快（6.9% vs -5.9%），BED BATH & BEYOND, INC.自由现金流更多（$-12.8M vs $-14.3M），过去两年Apellis Pharmaceuticals, Inc.的营收复合增速更高（7.7% vs -21.1%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
Bed Bath & Beyond曾是美国大型零售连锁企业，主营家居用品、家具及特色家居商品，总部位于新泽西州尤宁郡，业务覆盖美国与加拿大，曾经一度跻身财富世界500强与福布斯全球2000强榜单。该企业于2023年4月申请破产清算，关闭所有剩余门店，现已转型为线上零售品牌。
APLS vs BBBY — 直观对比
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $247.8M |
| 净利润 | $-59.0M | $-16.4M |
| 毛利率 | — | 23.9% |
| 营业利润率 | -25.6% | 68.8% |
| 净利率 | -29.5% | -6.6% |
| 营收同比 | -5.9% | 6.9% |
| 净利润同比 | -62.2% | 58.9% |
| 每股收益（稀释后） | $-0.40 | $-0.24 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q1 26 | — | $247.8M | ||
| Q4 25 | $199.9M | $273.4M | ||
| Q3 25 | $458.6M | $257.2M | ||
| Q2 25 | $178.5M | $282.3M | ||
| Q1 25 | $166.8M | $231.7M | ||
| Q4 24 | $212.5M | $303.2M | ||
| Q3 24 | $196.8M | $311.4M | ||
| Q2 24 | $199.7M | $398.1M |
| Q1 26 | — | $-16.4M | ||
| Q4 25 | $-59.0M | $-20.9M | ||
| Q3 25 | $215.7M | $-4.5M | ||
| Q2 25 | $-42.2M | $-19.3M | ||
| Q1 25 | $-92.2M | $-39.9M | ||
| Q4 24 | $-36.4M | $-81.3M | ||
| Q3 24 | $-57.4M | $-61.0M | ||
| Q2 24 | $-37.7M | $-42.6M |
| Q1 26 | — | 23.9% | ||
| Q4 25 | — | 24.6% | ||
| Q3 25 | — | 25.3% | ||
| Q2 25 | — | 23.7% | ||
| Q1 25 | — | 25.1% | ||
| Q4 24 | — | 23.0% | ||
| Q3 24 | — | 21.2% | ||
| Q2 24 | — | 20.1% |
| Q1 26 | — | 68.8% | ||
| Q4 25 | -25.6% | -4.8% | ||
| Q3 25 | 48.7% | -4.8% | ||
| Q2 25 | -18.6% | -4.4% | ||
| Q1 25 | -50.0% | -10.0% | ||
| Q4 24 | -12.3% | -11.3% | ||
| Q3 24 | -24.0% | -14.5% | ||
| Q2 24 | -14.7% | -11.8% |
| Q1 26 | — | -6.6% | ||
| Q4 25 | -29.5% | -7.6% | ||
| Q3 25 | 47.0% | -1.8% | ||
| Q2 25 | -23.6% | -6.8% | ||
| Q1 25 | -55.3% | -17.2% | ||
| Q4 24 | -17.1% | -26.8% | ||
| Q3 24 | -29.2% | -19.6% | ||
| Q2 24 | -18.9% | -10.7% |
| Q1 26 | — | $-0.24 | ||
| Q4 25 | $-0.40 | $-0.26 | ||
| Q3 25 | $1.67 | $-0.07 | ||
| Q2 25 | $-0.33 | $-0.34 | ||
| Q1 25 | $-0.74 | $-0.74 | ||
| Q4 24 | $-0.30 | $-1.68 | ||
| Q3 24 | $-0.46 | $-1.33 | ||
| Q2 24 | $-0.30 | $-0.93 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $135.8M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $370.1M | $202.5M |
| 总资产 | $1.1B | $404.5M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q1 26 | — | $135.8M | ||
| Q4 25 | $466.2M | $175.3M | ||
| Q3 25 | $479.2M | $167.4M | ||
| Q2 25 | $370.0M | $120.6M | ||
| Q1 25 | $358.4M | $114.6M | ||
| Q4 24 | $411.3M | $159.2M | ||
| Q3 24 | $396.9M | $140.4M | ||
| Q2 24 | $360.1M | $186.2M |
| Q1 26 | — | $202.5M | ||
| Q4 25 | $370.1M | $217.6M | ||
| Q3 25 | $401.2M | $202.6M | ||
| Q2 25 | $156.3M | $130.9M | ||
| Q1 25 | $164.2M | $143.4M | ||
| Q4 24 | $228.5M | $162.7M | ||
| Q3 24 | $237.1M | $196.2M | ||
| Q2 24 | $264.3M | $250.4M |
| Q1 26 | — | $404.5M | ||
| Q4 25 | $1.1B | $425.5M | ||
| Q3 25 | $1.1B | $414.4M | ||
| Q2 25 | $821.4M | $358.1M | ||
| Q1 25 | $807.3M | $363.7M | ||
| Q4 24 | $885.1M | $402.0M | ||
| Q3 24 | $901.9M | $428.3M | ||
| Q2 24 | $904.5M | $496.8M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | $-11.8M |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | $-12.8M |
| 自由现金流率自由现金流/营收 | -7.1% | -5.2% |
| 资本支出强度资本支出/营收 | 0.1% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $45.0M | $-24.8M |
8季度趋势，按日历期对齐
| Q1 26 | — | $-11.8M | ||
| Q4 25 | $-14.2M | $-6.5M | ||
| Q3 25 | $108.5M | $-15.1M | ||
| Q2 25 | $4.4M | $15.8M | ||
| Q1 25 | $-53.4M | $-50.9M | ||
| Q4 24 | $19.4M | $-21.7M | ||
| Q3 24 | $34.1M | $-42.1M | ||
| Q2 24 | $-8.3M | $-75.9M |
| Q1 26 | — | $-12.8M | ||
| Q4 25 | $-14.3M | $-8.6M | ||
| Q3 25 | $108.3M | $-17.4M | ||
| Q2 25 | $4.4M | $14.0M | ||
| Q1 25 | $-53.4M | $-52.1M | ||
| Q4 24 | $19.3M | $-24.7M | ||
| Q3 24 | — | $-45.5M | ||
| Q2 24 | $-8.4M | $-80.4M |
| Q1 26 | — | -5.2% | ||
| Q4 25 | -7.1% | -3.2% | ||
| Q3 25 | 23.6% | -6.8% | ||
| Q2 25 | 2.5% | 5.0% | ||
| Q1 25 | -32.0% | -22.5% | ||
| Q4 24 | 9.1% | -8.1% | ||
| Q3 24 | — | -14.6% | ||
| Q2 24 | -4.2% | -20.2% |
| Q1 26 | — | — | ||
| Q4 25 | 0.1% | 0.8% | ||
| Q3 25 | 0.0% | 0.9% | ||
| Q2 25 | 0.0% | 0.6% | ||
| Q1 25 | 0.0% | 0.5% | ||
| Q4 24 | 0.0% | 1.0% | ||
| Q3 24 | 0.0% | 1.1% | ||
| Q2 24 | 0.0% | 1.1% |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 0.50× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
BBBY
暂无分部数据
